INMUNE BIO INC

INMBNASDAQ

🏆 #4423 by market capEarnings Oct 28US Equity

$382.63▲ $1.15 (+0.30%)

Simulated price

🔔

Track INMB

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.3%

7d▲ 19031.5%

14d▲ 18519.5%

30d▲ 16536.1%

ytd▲ 24506.4%

1y▲ 18429.3%

🏦Market Cap

$53M

Small Cap

📈Revenue Growth (YoY)

+257.1%

High Growth

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $377.54 – $385.83
52-Week Range: $1.09 – $2.60
Volume: $2.80B
Avg Volume: $2.52B
Shares Outstanding: 26.6M
Next Earnings: Nov 4, 2026

Fundamentals Snapshot

Annual Revenue: $50,000
Last Q Revenue: $12,132
P/E Ratio: -2.9
P/S Ratio: 0.0x
EPS (TTM): $-0.69
Dividend Yield: 0.00%
Dilution (1yr): +19.3%

Why Investors Own INMB

✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
✓Healthy economics — 74% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INMUNE BIO INC

INMB

Financial Trends

Revenue

$50K▲ +257.1% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$31M▼ −27.6% YoY

Free Cash Flow

−$24M▼ −29.2% YoY

Shares Outstanding

26.6M▲ +19.3% YoY

Net Cash

$24M▲ +$3M YoY

StockOtter · stockotter.space

About INMUNE BIO INC

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

🦦